Clinical Trial

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Study acronym: ASCEND-IBD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Trial Details
NCT Number NCT07113522
Lead Sponsor Mirador Therapeutics, Inc.
Conditions Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Enrollment 140 participants
Start Date 2025-06-26
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-12